Modulation of Platelet Activation in Chronic Kidney Disease Patients on Erythropoiesis-Stimulating Agents
نویسندگان
چکیده
منابع مشابه
Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease.
Anemia is common in patients with advanced chronic kidney disease (CKD). Though erythropoiesis-stimulating agents (ESAs) have been strongly endorsed in guidelines, it is of particular financial interest. Recently, the reimbursement of ESAs in non-dialytic patients was started by the Korean National Health Insurance System. Thus, we investigated the impact of the reimbursement of ESAs on the ane...
متن کاملMeta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
BACKGROUND Previous meta-analyses suggest that treatment with erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) increases the risk for death. Additional randomized trials have been recently completed. PURPOSE To summarize the effects of ESA treatment on clinical outcomes in patients with anemia and CKD. DATA SOURCES MEDLINE (January 1966 to November 2009), EMBASE (Jan...
متن کاملExtended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
The recombinant human erythropoietins epoetins alfa and beta have relatively short half-lives ( approximately 24 h by subcutaneous route) and have traditionally been administered 2 or 3 times a week for the treatment of anaemia in patients with chronic kidney disease. However, multiple weekly injections are inconvenient for both the patient and the healthcare provider. With the introduction of ...
متن کاملErythropoiesis-stimulating agents for anaemia in chronic heart failure patients.
BACKGROUND Chronic heart failure (CHF) is a leading cause of morbidity and mortality worldwide. Anaemia is a common (12-55%) co-morbid condition and is associated with worsening symptoms and increased mortality. Anaemia is treatable and can be targeted in the treatment of patients with CHF. Erythropoiesis-stimulating agents (ESA), supplemented by iron therapy, are used to treat anaemia in chron...
متن کاملUtilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study
Intravenous (IV) iron and Erythropoiesis Stimulating Agents (ESAs) are recommended for anemia management in chronic kidney disease (CKD). This retrospective cohort study analyzed utilization patterns of IV iron and ESA in patients over 18 years of age admitted to University Health System Hospitals with a primary or secondary diagnosis of CKD between January 1, 2006 to December 31, 2008. A clust...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Applied Thrombosis/Hemostasis
سال: 2012
ISSN: 1076-0296,1938-2723
DOI: 10.1177/1076029611431954